Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set

Eun Sung Park, Rosalia Rabinovsky, Mark Carey, Bryan T. Hennessy, Roshan Agarwal, Wenbin Liu, Zhenlin Ju, Wanleng Deng, Yiling Lu, Hyun Goo Woo, Sang Bae Kim, Jae Ho Cheong, Levi A. Garraway, John N. Weinstein, Gordon B. Mills, Ju Seog Lee, Michael A. Davies

    Research output: Contribution to journalArticle

    67 Scopus citations

    Abstract

    Aberrations in oncogenes and tumor suppressors frequently affect the activity of critical signal transduction pathways. To analyze systematically the relationship between the activation status of protein networks and other characteristics of cancer cells, we did reverse phase protein array (RPPA) profiling of the NCI60 cell lines for total protein expression and activation-specific markers of critical signaling pathways. To extend the scope of the study, we merged those data with previously published RPPA results for the NCI60. Integrative analysis of the expanded RPPA data set revealed five major clusters of cell lines and five principal proteomic signatures. Comparison of mutations in the NCI60 cell lines with patterns of protein expression showed significant associations for PTEN, PIK3CA, BRAF, and APC mutations with proteomic clusters. PIK3CA and PTEN mutation enrichment were not cell lineage-specific but were associated with dominant yet distinct groups of proteins. The five RPPA-defined clusters were strongly associated with sensitivity to standard anticancer agents. RPPA analysis identified 27 protein features significantly associated with sensitivity to paclitaxel. The functional status of those proteins was interrogated in a paclitaxel whole genome small interfering RNA (siRNA) library synthetic lethality screen and confirmed the predicted associations with drug sensitivity. These studies expand our understanding of the activation status of protein networks in the NCI60 cancer cell lines, demonstrate the importance of the direct study of protein expression and activation, and provide a basis for further studies integrating the information with other molecular and pharmacological characteristics of cancer.

    Original languageEnglish (US)
    Pages (from-to)257-267
    Number of pages11
    JournalMolecular cancer therapeutics
    Volume9
    Issue number2
    DOIs
    StatePublished - Feb 2010

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set'. Together they form a unique fingerprint.

  • Cite this

    Park, E. S., Rabinovsky, R., Carey, M., Hennessy, B. T., Agarwal, R., Liu, W., Ju, Z., Deng, W., Lu, Y., Woo, H. G., Kim, S. B., Cheong, J. H., Garraway, L. A., Weinstein, J. N., Mills, G. B., Lee, J. S., & Davies, M. A. (2010). Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Molecular cancer therapeutics, 9(2), 257-267. https://doi.org/10.1158/1535-7163.MCT-09-0743